SLIT vs OIT: Sublingual vs Oral Immunotherapy Compared

The main difference is the route of delivery and the allergen they treat. SLIT, sublingual immunotherapy, places a liquid allergen extract under the tongue and is used mainly for airborne allergies like pollen, dust mites, mold and pet dander. OIT, oral immunotherapy, has the patient swallow a measured dose of an actual food protein to build tolerance to a food allergy such as peanut, milk or egg. Because the food is ingested directly, OIT carries a higher risk of systemic allergic reactions than SLIT, whose side effects are usually mild and local. The two are not interchangeable and are chosen based on whether the trigger is airborne or a food.

Published data show that SLIT generally has a lower risk of systemic allergic reactions than OIT, though no immunotherapy is completely without risk. In SLIT, most side effects are mild and local, such as itching of the mouth, throat or ears, and in our program fewer than 0.1% of patients have systemic reactions. OIT, because it delivers food protein into the body, more often triggers systemic reactions, which is why dose increases are typically supervised in a clinic and an epinephrine auto-injector is prescribed. Saying SLIT carries a lower systemic risk is accurate, but the appropriate therapy depends on the allergen being treated, not safety alone.

SLIT for food allergies is being studied and is sometimes used, but the evidence is thinner and less mature than for airborne allergens, and food SLIT is considered especially off-label. For most established food-allergy desensitization, oral immunotherapy is the more common approach because it can raise the tolerated dose more substantially, albeit with more reactions. SLIT for food may offer a gentler side-effect profile but typically smaller increases in tolerance. Any food immunotherapy should be directed and supervised by an allergist, because food reactions can be severe. Discuss with your provider which approach, if any, fits your specific food allergy.

OIT requires closer supervision because swallowing food protein carries a higher chance of triggering a systemic allergic reaction, including potentially serious ones. For that reason, dose escalations in OIT are usually performed in a medical setting where staff can monitor for reactions and treat them quickly, and patients are prescribed an epinephrine auto-injector. SLIT, by contrast, is delivered under the tongue and produces mostly mild, local reactions, so after appropriate initial guidance it is generally taken daily at home. The supervision difference reflects the different reaction risks of the two routes, not a difference in how well either ultimately works.

Neither SLIT nor OIT is a guaranteed cure. Both are forms of immunotherapy that gradually change how the immune system responds to an allergen, which can reduce symptoms or raise the amount of a food a person can tolerate. SLIT may provide long-term relief from airborne allergy symptoms when continued for several years, while OIT aims to raise the tolerance threshold so accidental food exposures are less dangerous. In both cases, benefit can fade if treatment stops, and results vary from person to person. They modify the allergic response over time rather than permanently eliminating the allergy.